ICMR Launches Medical Innovations Patent Mitra – 41 Public‑Health Technologies Transferred to Industry

The ICMR organised the country's largest biomedical technology‑transfer event, Medical Innovations Patent Mitra (MIPM) – Innovators‑to‑Industry (I2I) Connect – at the Manekshaw Centre, New Delhi. The event aimed to move indigenous research from labs to the market through strong public‑private partnerships. Key Developments Inauguration by Shri Prataprao Ganpatrao Jadhav , Union MoS (Independent Charge) for Ayush and MoS for Health, with NITI Aayog member Prof. Gobardhan Das in attendance. Transfer of 41 public‑health technologies from ICMR institutes to industry partners for development, manufacturing and commercialization. First‑ever transfer of well‑characterised biomaterials of KFD virus and Chandipura virus to industry. Release of the ‘ Indian Biomedical Patent Landscape Report ’ and the ‘ Technology Compendium ’ to strengthen the IP ecosystem. Showcasing of more than 100 technologies in diagnostics, therapeutics and medical devices developed by ICMR, researchers and start‑ups. Important Facts Vaccines transferred include glycoconjugate and recombinant vaccines for Typhoid and Paratyphoid . Diagnostic platforms transferred for Japanese Encephalitis , Tuberculosis and Mpox . The event underscores the role of the Ministry of Health and Family Welfare in promoting health‑technology innovation. Goal aligns with the vision of a “Viksit Bharat 2047” through stronger public‑private collaboration. UPSC Relevance Understanding MIPM helps aspirants link three core UPSC themes: (i) Science & Technology policy – the government’s push for indigenous health tech; (ii) Health sector governance – role of ICMR and MoHFW in translating research into public health solutions; (iii) Public‑Private Partnerships – a model for scaling innovations, relevant for GS‑3 (Science & Technology) and GS‑2 (Polity) questions on policy implementation. Way Forward For the initiative to sustain momentum, the following steps are essential: strengthening IP protection , creating a dedicated fund for scaling transferred technologies, and establishing a monitoring mechanism to track commercial outcomes. Continuous engagement between innovators, industry and regulatory bodies will ensure that India not only consumes but also exports affordable health technologies, supporting the broader goal of self‑reliance in the biomedical sector.